Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Adicet Bio Inc ACET

Healthcare Biotechnology
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy... see more

Current News (NDAQ:ACET)

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

Business Wire 12 days ago

Adicet Bio Announces Reverse Stock Split

Business Wire December 26, 2025

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 28, 2025

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Business Wire November 5, 2025

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 31, 2025

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Business Wire October 28, 2025

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Business Wire October 16, 2025

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Business Wire October 7, 2025

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Business Wire October 7, 2025
View More News ››

Opinion & Analysis (NDAQ:ACET)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ACET)

7 REASONS TO PUT ADICET BIO ON YOUR WATCHLIST!

$ACET   Adicet Bio (NASDAQ: ACET) is a biotechnology Company working on bringing allogeneic gamma delta T cell therapies for...
AviseAnalytics - January 24, 2022

really now

this has gone from $20 in 2018 to $2.31 now. I'm an old guy and would like to invest but if it's been too good to be true for...
yllanycrop - August 16, 2020

still holding this stock

should be a breakout to the upside soon,so glta.
coolfooldumbguy - December 12, 2019

CASH over $100 Million,NO DEBT,FREE Company

what's not to like,the company could buy back all its shares with its cash position,so glta.
coolfooldumbguy - November 18, 2019

it's a buy today for me

was on my watchlist and it was way oversold.so glta.
coolfooldumbguy - November 18, 2019

$1 a share.

Yes please. 100m in bank. This is severly undervalued.. $2 in the next few weeks. 100% gain. Thanks.
Diamfrank07 - November 17, 2019
View more Bullboard ››

Oregen Energy Corp

Oregen Energy Corp

Oregen Energy Corp., an energy and resource exploration company, focuses on acquiring and advancing natural resources ...
View More »

Podcasts